KR102324116B1 - 암의 치료를 위한 방법 및 조성물 - Google Patents

암의 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102324116B1
KR102324116B1 KR1020157034532A KR20157034532A KR102324116B1 KR 102324116 B1 KR102324116 B1 KR 102324116B1 KR 1020157034532 A KR1020157034532 A KR 1020157034532A KR 20157034532 A KR20157034532 A KR 20157034532A KR 102324116 B1 KR102324116 B1 KR 102324116B1
Authority
KR
South Korea
Prior art keywords
seq
omomyc
cancer
arg
polypeptide
Prior art date
Application number
KR1020157034532A
Other languages
English (en)
Korean (ko)
Other versions
KR20160013058A (ko
Inventor
라우라 소우섹
마리에-이브 뷸리에우
Original Assignee
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 filed Critical 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론
Publication of KR20160013058A publication Critical patent/KR20160013058A/ko
Application granted granted Critical
Publication of KR102324116B1 publication Critical patent/KR102324116B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157034532A 2013-05-07 2014-05-07 암의 치료를 위한 방법 및 조성물 KR102324116B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382167.8 2013-05-07
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer
PCT/EP2014/059315 WO2014180889A1 (en) 2013-05-07 2014-05-07 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20160013058A KR20160013058A (ko) 2016-02-03
KR102324116B1 true KR102324116B1 (ko) 2021-11-11

Family

ID=48366303

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157034532A KR102324116B1 (ko) 2013-05-07 2014-05-07 암의 치료를 위한 방법 및 조성물

Country Status (25)

Country Link
US (2) US10370434B2 (pt)
EP (4) EP2801370A1 (pt)
JP (2) JP6722103B2 (pt)
KR (1) KR102324116B1 (pt)
CN (1) CN105378084B (pt)
AU (1) AU2014264642B2 (pt)
BR (2) BR112015028115B1 (pt)
CA (1) CA2911863A1 (pt)
CY (1) CY1121849T1 (pt)
DK (1) DK2994533T3 (pt)
EA (2) EA202090683A3 (pt)
ES (1) ES2733515T3 (pt)
HK (2) HK1219756A1 (pt)
HR (1) HRP20191330T1 (pt)
HU (1) HUE045615T2 (pt)
IL (2) IL242483B (pt)
LT (1) LT2994533T (pt)
ME (1) ME03509B (pt)
MX (1) MX370792B (pt)
PL (1) PL2994533T3 (pt)
PT (1) PT2994533T (pt)
RS (1) RS59276B1 (pt)
SG (2) SG11201509131VA (pt)
SI (1) SI2994533T1 (pt)
WO (1) WO2014180889A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
US20190135868A1 (en) * 2016-04-29 2019-05-09 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
CN111405903A (zh) * 2017-09-08 2020-07-10 Idp研发制药有限公司 多发性骨髓瘤的新疗法
WO2019108134A1 (en) * 2017-11-29 2019-06-06 Agency For Science, Technology And Research Chimeric molecule for targeting c-myc in cells
WO2019199803A1 (en) * 2018-04-09 2019-10-17 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CN113557035A (zh) * 2019-01-12 2021-10-26 卫理公会医院 自组装肽纳米颗粒和其用途
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
SG11202109066RA (en) * 2019-03-19 2021-09-29 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
WO2021041953A1 (en) * 2019-08-30 2021-03-04 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
CN115925975A (zh) * 2022-08-03 2023-04-07 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019176A1 (en) 1992-03-23 1993-09-30 Imperial Cancer Research Technology Limited Leucine zippers
CN1968689A (zh) 2004-06-18 2007-05-23 狄洛特医药有限公司 包含多不饱和脂肪酸和至少一种免疫抑制剂或抗肿瘤剂的药物组合物
US20090304805A1 (en) 2005-02-18 2009-12-10 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2011057713A1 (de) 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidmaschine für lebensmittel
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
EP2544686A4 (en) 2010-02-05 2013-06-26 Whitehead Biomedical Inst COMBINED METHODS FOR THE TREATMENT OF DISEASES
CN103096932B (zh) * 2010-06-14 2016-10-12 弗·哈夫曼-拉罗切有限公司 细胞穿透肽及其用途
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019176A1 (en) 1992-03-23 1993-09-30 Imperial Cancer Research Technology Limited Leucine zippers
CN1968689A (zh) 2004-06-18 2007-05-23 狄洛特医药有限公司 包含多不饱和脂肪酸和至少一种免疫抑制剂或抗肿瘤剂的药物组合物
US20070219271A1 (en) 2004-06-18 2007-09-20 Tillotts Pharma Ag Pharmaceutical Compositions Containing Pufa And At Least One Of An Immunosuppressive Agent Or An Antineoplastic Agent
US20090304805A1 (en) 2005-02-18 2009-12-10 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2011057713A1 (de) 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidmaschine für lebensmittel
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Biotechnology, Vol. 22, pp.888-893 (2011.)*
Genes & Develop., Vol. 27, No. 5, pp.504-513 (2013. 3. 1.)*
Oncogene, Vol. 17, pp.2463-2472 (1998)*

Also Published As

Publication number Publication date
US11339205B2 (en) 2022-05-24
JP6790148B2 (ja) 2020-11-25
ES2733515T3 (es) 2019-11-29
EP2801370A1 (en) 2014-11-12
JP2019147792A (ja) 2019-09-05
KR20160013058A (ko) 2016-02-03
ME03509B (me) 2020-04-20
AU2014264642B2 (en) 2020-09-17
HUE045615T2 (hu) 2020-01-28
HK1251494A1 (zh) 2019-02-01
CN105378084A (zh) 2016-03-02
LT2994533T (lt) 2019-08-12
IL273090B (en) 2022-06-01
US20190382468A1 (en) 2019-12-19
US10370434B2 (en) 2019-08-06
EA202090683A3 (ru) 2020-09-30
AU2014264642A1 (en) 2015-11-19
EP3338789A1 (en) 2018-06-27
BR112015028115B1 (pt) 2023-11-21
EP2994533B1 (en) 2019-05-01
PL2994533T3 (pl) 2020-03-31
JP2016520056A (ja) 2016-07-11
DK2994533T3 (da) 2019-07-01
HRP20191330T1 (hr) 2019-10-18
EA201690159A1 (ru) 2016-05-31
HK1219756A1 (zh) 2017-04-13
BR122020017819B1 (pt) 2023-11-21
SG11201509131VA (en) 2015-12-30
WO2014180889A8 (en) 2015-06-18
WO2014180889A1 (en) 2014-11-13
IL273090A (en) 2020-04-30
CN105378084B (zh) 2019-07-05
CY1121849T1 (el) 2020-07-31
JP6722103B2 (ja) 2020-07-15
CA2911863A1 (en) 2014-11-13
SI2994533T1 (sl) 2019-09-30
PT2994533T (pt) 2019-08-05
EP3545966A1 (en) 2019-10-02
EP2994533A1 (en) 2016-03-16
MX2015015518A (es) 2016-07-21
RS59276B1 (sr) 2019-10-31
MX370792B (es) 2020-01-08
SG10201709101VA (en) 2017-12-28
US20160122415A1 (en) 2016-05-05
IL242483B (en) 2020-03-31
EA202090683A2 (ru) 2020-06-30
BR112015028115A2 (pt) 2017-10-17
EA035463B1 (ru) 2020-06-19

Similar Documents

Publication Publication Date Title
US11339205B2 (en) Methods and compositions for the treatment of cancer
Bolhassani et al. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides
US11427621B2 (en) Methods and compositions for the treatment of cancer
US10188699B2 (en) CAPCNA peptide therapeutics for cancer
EA042570B1 (ru) Способы и композиции для лечения рака

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant